Challenges and opportunities for conceiving genetically diverse sickle cell mice.

Abstract excerpt

A milestone in sickle cell disease (SCD) therapeutics was achieved in December 2023 with the FDA-approved gene therapy for patients aged 12 years and older. However, these therapies may only suit a fraction of patients because of cost or health risks. A better understanding of SCD outcome heterogeneity is needed to propose patient-specific pharmacological interventions. To achieve this, humanized and genetically...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anemia, Sickle Cell
• Share to Disease Models, Animal
• Share to SCD gene